Loading…

Interstitial nephritis in melanoma patients secondary to PD-1 checkpoint inhibitor

Immune checkpoint inhibitors have become the first line therapy in melanoma treatment and their use is extending to other malignancies. However, we are still learning about immune side effects produced by these drugs and their severity especially in patients with history of inflammatory diseases. We...

Full description

Saved in:
Bibliographic Details
Published in:Journal for immunotherapy of cancer 2017-01, Vol.5 (1), p.3, Article 3
Main Authors: Escandon, Julia, Peacock, Stephanie, Trabolsi, Asaad, Thomas, David B, Layka, Ayman, Lutzky, Jose
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Immune checkpoint inhibitors have become the first line therapy in melanoma treatment and their use is extending to other malignancies. However, we are still learning about immune side effects produced by these drugs and their severity especially in patients with history of inflammatory diseases. We present two cases of metastatic melanoma treated with nivolumab and pembrolizumab (anti PD-1). Both patients developed acute interstitial nephritis during immune checkpoint therapy. We emphasize the causal association between immune checkpoint inhibitors and the nephritis. The timing of drug administration and appearance of nephritis is suggestive of a causal relation between the checkpoint inhibitor therapy and this adverse event. Although uncommon, some side effects from checkpoint inhibitors can be severe and may need to be addressed with immunosuppression. Given the increasing frequency of immunotherapy use, awareness should be raised in regards to immune side effects and their appropriate management.
ISSN:2051-1426
2051-1426
DOI:10.1186/s40425-016-0205-2